Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improves on accuracy and extending usage from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, of its new continuous glucose monitoring system from the FDA. This product received a CE mark in November 2009. In 2013, development to integrate with Insulet discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018. Dexcom’s first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This new device improved hypoglycemic accuracy by 30% It also offered a longer range of transmission between the sensor and receiver as well as a color LCD display. The G4 Platinum was later approved by the FDA for use in patients ages 2-17 in February 2014. Dexcom then received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the “Share” and “Follow” smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has Bluetooth built into the transmitter, enabling it to send data to the a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 then received a CE Mark in September 2015.
Partnerships
Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem’s t:slim X2 insulin pump and the Dexcom G6 to “to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes.” Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo’s platform. This integration will allow Livongo to incorporate the CGM data along with other patient data to provide health insights based on its algorithm to help patients manage their diabetes. In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet’s tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery. This will give the ability to adjust insulin doses based on Insulet’s algorithm or through their smartphone. The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management. BlueStar will combine the CGM data with information on patients’ activity, nutrition, sleep and other factors to help them manage their condition.
